SEARCH

SEARCH BY CITATION

References

  • Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., Antipin, Y., Reva, B., Goldberg, A.P., Sander, C. & Schultz, N. (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discovery, 2, 401404.
  • Cooper, G.M., Stone, E.A., Asimenos, G., Green, E.D., Batzoglou, S. & Sidow, A. (2005) Distribution and intensity of constraint in mammalian genomic sequence. Genome Research, 15, 901913.
  • Futreal, P.A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N. & Stratton, M.R. (2004) A census of human cancer genes. Nature Reviews Cancer, 4, 177183.
  • Grimwade, D., Hills, R.K., Moorman, A.V., Walker, H., Chatters, S., Goldstone, A.H., Wheatley, K., Harrison, C.J. & Burnett, A.K. (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood, 116, 354365.
  • Leith, C.P., Kopecky, K.J., Godwin, J., McConnell, T., Slovak, M.L., Chen, I.M., Head, D.R., Appelbaum, F.R. & Willman, C.L. (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood, 89, 33233329.
  • Link, D.C., Schuettpelz, L.G., Shen, D., Wang, J., Walter, M.J., Kulkarni, S., Payton, J.E., Ivanovich, J., Goodfellow, P.J., Le Beau, M., Koboldt, D.C., Dooling, D.J., Fulton, R.S., Bender, R.H., Fulton, L.L., Delehaunty, K.D., Fronick, C.C., Appelbaum, E.L., Schmidt, H., Abbott, R., O'Laughlin, M., Chen, K., McLellan, M.D., Varghese, N., Nagarajan, R., Heath, S., Graubert, T.A., Ding, L., Ley, T.J., Zambetti, G.P., Wilson, R.K. & Mardis, E.R. (2011) Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. Journal of the American Medical Association, 305, 15681576.
  • McNerney, M.E., Brown, C.D., Wang, X., Bartom, E.T., Karmakar, S., Bandlamudi, C., Yu, S., Ko, J., Sandall, B.P., Stricker, T., Anastasi, J., Grossman, R.L., Cunningham, J.M., Le Beau, M.M. & White, K.P. (2013) CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood, 121, 975983.
  • Schoch, C., Kern, W., Schnittger, S., Hiddemann, W. & Haferlach, T. (2004) Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia, 18, 120125.
  • Side, L.E., Curtiss, N.P., Teel, K., Kratz, C., Wang, P.W., Larson, R.A., Le Beau, M.M. & Shannon, K.M. (2004) RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Genes Chromosomes Cancer, 39, 217223.
  • Smith, S.M., Le Beau, M.M., Huo, D., Karrison, T., Sobecks, R.M., Anastasi, J., Vardiman, J.W., Rowley, J.D. & Larson, R.A. (2003) Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood, 102, 4352.
  • Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO Classification of Tumours of Haematopoieitc and Lymphoid Tissues. International Agency for Research on Cancer, Lyon, France.
  • TCGA (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. The Cancer Genome Atlas Research Network. New England Journal of Medicine, 368, 20592074.